The rapid enrollment design for Phase I clinical trials

Area of Science:

• Oncology
• Clinical Trial Design
• Biostatistics

Background:

• Phase I oncology trials aim to determine the maximum tolerated dose (MTD) of a new agent.
• Traditional dose-finding methods can be slow, leading to suboptimal dose assignments.
• Efficient dose selection is crucial for patient safety and trial progression.

Purpose of the Study:

• To propose a novel dose-finding design for Phase I oncology trials.
• To enable immediate dose assignment for newly enrolled patients based on observed toxicity data.
• To enhance safety and efficiency in fast-accruing trials.

Main Methods:

• A dose-finding design is proposed where each new patient is assigned to the dose most likely to be the target dose.
• The core assumption is a non-decreasing dose-toxicity curve.
• A conservative rule assigning temporary fractional toxicities for patients in follow-up is introduced to manage limited toxicity information in rapid trials.

Main Results:

• The proposed design allows for prompt dose assignment upon patient enrollment.
• The conservative rule mitigates risks associated with limited toxicity data in fast-accruing trials.
• The method is designed to be adaptable and safe for early-phase oncology studies.

Conclusions:

• The proposed dose-finding design offers an efficient and safe approach for Phase I oncology trials.
• Immediate dose assignment based on observed data is feasible and beneficial.
• Implementing conservative rules and safety protocols is recommended for fast-accruing trials.